Skip to content

Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Magnetic Stimulation

Neurocircuitry of OCD: Effects Of Modulation

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02704117
Enrollment
19
Registered
2016-03-09
Start date
2015-06-30
Completion date
2024-02-29
Last updated
2023-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder

Brief summary

The purpose of this study is to test the effects of non-invasive neuromodulation, transcranial magnetic stimulation on brain function in individuals with obsessive-compulsive disorder (OCD). This study is focused on the mechanism(s) by which brain stimulation might change the functioning of regions implicated in OCD, and thereby inform possible future therapeutic uses.

Interventions

DEVICETranscranial Magentic Stimulation

This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks

Sponsors

University of Rochester
CollaboratorOTHER
Harvard University
CollaboratorOTHER
University of Pittsburgh
CollaboratorOTHER
University of Puerto Rico
CollaboratorOTHER
Butler Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Current primary OCD diagnosis and current Y-BOCS total score of ≥16 * 18-70 years of age * Ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent * No use of psychiatric medications or stable psychiatric medication use for a minimum of 6 week prior to study entry * Ongoing psychotherapy allowed if already established for three months or more before study entry

Exclusion criteria

* History of primary psychotic disorder or bipolar disorder * Present acute suicidality * History of head injury, epilepsy, or other clinically significant neurological illness except tic disorders * Active systemic medical (metabolic, endocrine, chronic inflammatory, vascular, autoimmune) disease * Premorbid intelligence quotient (IQ) estimate \< 80 * Visual disturbance (\<20/40 Snellen visual acuity, corrected) * Current, or alcohol or illicit substance abuse/dependence in the last 3 months * Contraindications to TMS or MRI: metallic foreign objects, e.g., aneurysm clips/pacemakers, or questionable history of metal fragments, claustrophobia * Women who are pregnant or breastfeeding. All women participants of reproductive age are required to have a negative pregnancy test prior to enrollment and use medically acceptable birth control throughout the study (barrier and/or oral contraceptives) * Current psychotic symptoms * An increased risk of seizure, determined by history * Medications judged to notably affect cortical excitability e.g., anticonvulsants or high-dose benzodiazepines (\> 4 mg/day of clonazepam or equivalent) * Predominant hoarding symptoms

Design outcomes

Primary

MeasureTime frame
Change in activation of pre-supplementary motor area/dorsal anterior cingulate cortex (pSMA/dACC) on functional magnetic resonance imaging (fMRI) during the Multi-Source Interference task (MSIT)Baseline and 6 months

Secondary

MeasureTime frame
Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS)Baseline and 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026